Tekla Capital Management LLC Adaptimmune Therapeutics PLC Transaction History

Tekla Capital Management LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2020 May 14, 2020	SELL	$1.2 - $4.52 $92,473 - $348,315	-77,061 Closed	0 $0
Q3 2019 Nov 13, 2019	SELL	$1.43 - $3.81 $216,552 - $576,967	-151,435 Reduced 66.27%	77,061 $116,000
Q4 2018 Feb 13, 2019	SELL	$3.76 - $14.16 $462,938 - $1.74 Million	-123,122 Reduced 35.02%	228,496 $1.31 Million
Q3 2018 Nov 13, 2018	SELL	$8.27 - $13.56 $4.17 Million - $6.83 Million	-503,850 Reduced 58.9%	351,618 $4.77 Million
Q1 2018 May 14, 2018	SELL	$7.1 - $11.56 $567,290 - $923,644	-79,900 Reduced 8.54%	855,468 $9.61 Million
Q3 2017 Nov 13, 2017	SELL	$4.93 - $8.93 $2.62 Million - $4.74 Million	-531,000 Reduced 36.21%	935,368 $7.66 Million
Q2 2017 Aug 14, 2017	BUY	N/A	1,466,368	1,466,368 $6.58 Million

152M

78.5K

36.5K

Ticker ADAP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 163,370,000
Market Cap $160M
Description
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4...

Get notified when there are updates to the investment portfolio of Tekla Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Tekla Capital Management LLC with notifications on news.